- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01301794
Lovaza Mechanisms of Action
February 21, 2013 updated by: Jorge Plutzky, Brigham and Women's Hospital
Study of the Effects of Lovaza (Omega 3 Fatty Acids) On Lipoprotein Particles and Their Transcriptional Effects
High levels of triglycerides is a common abnormality found in patients with diabetes and also cardiovascular disease, and may contribute to the risk for both.
Omega 3 fatty acids, as found enriched in fish and also in the commercial agent called Lovaza lower triglyceride levels.
Prior work from the investigators group demonstrated that an enzyme responsible for the break down of triglycerides - lipoprotein lipase - generates molecules that can activate a specific nuclear receptor known as PPAR-alpha.
This study investigates the hypothesis that taking Lovaza shifts the specific fatty acid content of triglyceride containing lipoproteins and increases the ability of those lipoproteins to activate PPAR-alpha.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study will investigate changes in lipid and other metabolic parameters as well as the ability of isolated lipoproteins to activate PPARs in the presence or absence of lipoprotein lipase in a cohort of normal healthy individuals with modest hypertriglyceridemia before and after a course of Lovaza.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jorge Plutzky, MD
- Phone Number: 617-525-4360
- Email: jplutzky@rics.bwh.harvard.edu
Study Contact Backup
- Name: Jon Brown, MD
- Phone Number: 617-525-4360
- Email: jbrown0@partners.org
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women's Hospital
-
Contact:
- Sutanuka Lahiri
- Phone Number: 617-525-6823
- Email: Sutanuka Lahiri <SLAHIRI@PARTNERS.ORG>
-
Contact:
- Jorge Plutzky
- Phone Number: 326-055-200
- Email: jplutzky@rics.bwh.harvard.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Otherwise healthy 21 to 65 year old men and women
- Triglycerides >150 < 500 mg/dL
Exclusion Criteria:
- Other lipid lowering medication including fish oil
- Major illnesses
- Diabetes
- Cardiovascular disease
- Abnormalities uncovered on screening blood work including undiagnosed diabetes, abnormal liver function tests, triglycerides > 500 mg/dL
- Indication for immediate statin therapy
- Pregnancy
- Contraindication for fish oil use or muscle biopsy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in lipoprotein metabolite content and their ability to activate PPAR-alpha in an established cell culture system.
Time Frame: 3 months
|
Enrolled subjects will serve as their own controls and will be studied at baseline and after 3 months of Lovaza.
The primary endpoint will test changes in lipoproteins as a function of their content and ability to activate PPAR-alpha in standard transfected cell culture systems.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in plasma markers for atherosclerosis
Time Frame: 3 months
|
Subjects will also be studied before and after Lovaza for changes in lipid profile and c- reactive protein
|
3 months
|
Change in plasma markers of diabetes
Time Frame: 3 months
|
Plasma markers of diabetes will be measure before and after Lovaza treatment for 3 months, specifically glucose and A1C levels
|
3 months
|
Changes in plasma markers of liver function
Time Frame: 3 months
|
Plasma levels of liver function tests, specifically ALT and AST before and after 3 months of Lovaza. This is not a safety issue since elevated triglycerides can cause increased liver function tests and fish oil (like Lovaza) can lower triglyceride levels and hence ALT and AST levels. |
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jorge Plutzky, MD, Brigham and Women's Hospital
- Study Director: Jonathan Brown, MD, Brigham and Women's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (Anticipated)
August 1, 2013
Study Completion (Anticipated)
August 1, 2014
Study Registration Dates
First Submitted
February 18, 2011
First Submitted That Met QC Criteria
February 22, 2011
First Posted (Estimate)
February 23, 2011
Study Record Updates
Last Update Posted (Estimate)
February 25, 2013
Last Update Submitted That Met QC Criteria
February 21, 2013
Last Verified
February 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BWHp001640
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate Hypertriglyceridemia.
-
Arrowhead PharmaceuticalsRecruitingSevere HypertriglyceridemiaUnited States
-
89bio, Inc.RecruitingSevere HypertriglyceridemiaUnited States, Bulgaria, Canada, Latvia, Spain, Austria, Belgium, Czechia, Georgia, Hungary, Poland, Puerto Rico, Argentina, Chile, France, Germany, United Kingdom
-
Ionis Pharmaceuticals, Inc.RecruitingSevere HypertriglyceridemiaUnited States, Germany, Israel, Spain, Netherlands, Australia, Hungary, Sweden, Denmark, Canada, France, Italy, Turkey, Finland, Bulgaria, Czechia, New Zealand, Norway, Poland, Portugal, Slovakia, South Africa, United Kingdom
-
Sancilio and Company, Inc.WithdrawnSevere Hypertriglyceridemia
-
Arrowhead PharmaceuticalsCompletedSevere HypertriglyceridemiaUnited States, Netherlands, Australia, Canada, New Zealand, Poland, Hungary, Germany
-
AstraZenecaCompletedSevere HypertriglyceridemiaUnited States, Hungary, India, Russian Federation, Denmark, Ukraine, Netherlands
-
AstraZenecaRadiant ResearchCompletedSevere HypertriglyceridemiaUnited States
-
Trygg Pharma, Inc.UnknownSevere HypertriglyceridemiaUnited States
-
National Taiwan University HospitalUnknownHypertriglyceridemia During PregnancyTaiwan
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
Clinical Trials on Omega 3 fatty acid (Lovaza)
-
Columbia UniversityGlaxoSmithKlineTerminated
-
University Hospitals Cleveland Medical CenterGlaxoSmithKline; Case Western Reserve University; The Campbell FoundationCompletedHIV Infections | Heart DiseaseUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompleted
-
University of Michigan Rogel Cancer CenterCompleted
-
University of PennsylvaniaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Withdrawn
-
Philip KernGlaxoSmithKline; National Institutes of Health (NIH); National Center for Research...CompletedMetabolic Syndrome | Insulin ResistanceUnited States
-
United States Department of DefenseGlaxoSmithKlineUnknownDepression | Mood Disorders | Combat Disorders | Stress DisordersIraq
-
University of Kansas Medical CenterActive, not recruitingColorectal Cancer | Lynch SyndromeUnited States
-
Brigham and Women's HospitalNational Institute of General Medical Sciences (NIGMS)CompletedBlister | Inflammation; Skin | ResolutionUnited States